Pliant Therapeutics Files Material Definitive Agreement
Ticker: PLRX · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $150.0 million, $50.0 million, $30.0 million, $10.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, pharmaceuticals
TL;DR
Pliant Therapeutics just signed a big deal, could be good news.
AI Summary
On March 11, 2024, Pliant Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or a significant partnership, as indicated by the filing of an 8-K. The company, headquartered in South San Francisco, CA, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing signals a significant development for Pliant Therapeutics, potentially involving new funding or a strategic collaboration that could impact its drug development pipeline and future financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new financial obligations or strategic shifts that carry inherent business risks.
Key Numbers
- 001-39303 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-4272481 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — Registrant
- March 11, 2024 (date) — Date of earliest event reported
- South San Francisco, CA (location) — Principal Executive Offices
- 260 Littlefield Avenue (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did Pliant Therapeutics enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.
What is the primary business of Pliant Therapeutics?
Pliant Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 11, 2024.
Where are Pliant Therapeutics' principal executive offices located?
Pliant Therapeutics' principal executive offices are located at 260 Littlefield Avenue, South San Francisco, CA 94080.
What is the SEC file number for Pliant Therapeutics?
The SEC file number for Pliant Therapeutics, Inc. is 001-39303.
Filing Stats: 1,440 words · 6 min read · ~5 pages · Grade level 12.7 · Accepted 2024-03-12 07:45:30
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Mar
- $150.0 million — up to an aggregate principal amount of $150.0 million (the "Term Loans"), of which $50.0 mill
- $50.0 million — .0 million (the "Term Loans"), of which $50.0 million is subject to the Lender's sole discret
- $30.0 million — he Company drew an initial Term Loan of $30.0 million on the Effective Date (inclusive of $10
- $10.0 million — ion on the Effective Date (inclusive of $10.0 million in principal amount previously outstand
- $70.0 million — ate) and may borrow up to an additional $70.0 million of Term Loans at its option upon the sa
Filing Documents
- d759675d8k.htm (8-K) — 33KB
- d759675dex991.htm (EX-99.1) — 10KB
- g759675g0312045936087.jpg (GRAPHIC) — 2KB
- 0001193125-24-065416.txt ( ) — 169KB
- plrx-20240311.xsd (EX-101.SCH) — 3KB
- plrx-20240311_lab.xml (EX-101.LAB) — 17KB
- plrx-20240311_pre.xml (EX-101.PRE) — 11KB
- d759675d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by the Company dated March 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: March 12, 2024 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer